CellCyte Genetics Corporation

CellCyte Genetics Corporation Announces Launch of Comprehensive German Web Site Powered by PRNewswire Investor Room Backend Technology

@@start.t1@@--------------------------------------------------------------------------------   ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for   the content of this announcement. --------------------------------------------------------------------------------@@end@@

new product

Bothell (euro adhoc) - BOTHELL, Wash., June 25 -- CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: CCYG) today reaffirmed its commitment to provide shareholders, potential investors and journalists with accurate and up-to-date information by launching a comprehensive Investor Room powered German Web site: http://www.cellcyte.de. Shareholders, investors and journalists seeking background information or sources for stories from CellCyte can access the information easily in the new German Web site, which was designed to meet their needs quickly and efficiently.

@@start.t2@@CellCyte's Investor Room Web site includes corporate background materials, executive bios, SEC filings, stock charts, news releases, and links to news and Web sites on stem cell research. The multimedia capabilities of the Investor Room system will allow CellCyte to communicate in detail regarding its technology and development plans. Further, investors and journalists can opt-in to receive email alerts on news from CellCyte.

      About CellCyte Genetics
      CellCyte Genetics is a biotechnology company engaged in the discovery,
development and commercialization of stem cell enabling therapeutic products.
CellCyte is developing products designed to allow more efficient delivery and
increased retention of adult stem cells to diseased organs, such as the heart.
The goal of these therapies is to increase the number of stem cells delivered to
a damaged organ, thereby markedly increasing organ healing and functional
restoration. The Company's lead product, CCG-TH30, is being developed to send
autologous bone marrow-derived (adult) stem cells to the heart of patients after
a heart attack.

      For further information see: http://www.cellcyte.com.

      Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.

SOURCE  CellCyte Genetics Corporation
      -0-                                              06/26/2008
      /Web site:  http://www.cellcyte.com
                         http://www.cellcyte.de /
      (CCYG CCYG.OB)@@end@@

@@start.t3@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: CellCyte Genetics Corporation
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
North America, investor relations of CellCyte Genetics Corporation
Phone: +1-877-688-5050
E-Mail: Investorrelations@cellcyte.com

Branche: Biotechnology
ISIN:      US15116P1030
WKN:        A0MLCV
Börsen:  Börse Frankfurt / Open Market
              Börse Berlin / free trade
              Börse Stuttgart / free trade
              Börse München / free trade



Weitere Meldungen: CellCyte Genetics Corporation

Das könnte Sie auch interessieren: